Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

Inclusion Criteria:

• Patients ≥18 years old.

• Patients granting the ICF unless exemption or exceptions mentioned below.

• Histological diagnosis of malignant neoplasia originating in the genitourinarysystem: kidney, renal pelvis, ureter, bladder, prostate, testicle and germinaltissue of other locations, urethra, penis, or seminal vesicles.

• Patients have started treatment with medications whose positive resolution offinancing by the Spanish National Health System for the aforementioned tumors hasbeen after January 1, 2023.

• Patients have started treatment after the official publication of the positiveresolution of financing of the drug under study by the National Health System. Thisrestriction is intended to avoid interference of the study with the marketingauthorization processes by the European Medicines Agency, and price andreimbursement negotiations by the Spanish health authorities.

• Patients have received treatment at the participating center.

Exclusion Criteria:

• Patients previously treated at another centre who have subsequently been referred toone of the participating centres. In this case, the patient will be included in thecentre where treatment was started, or in the second centre if the first is not partof this study.

• Patients who do not meet any of the inclusion criteria.

• Evidence of an express objection by the subject or his/her legal representative toparticipate in the study.